Opinion: TrumpRx has a fundamental flaw
Stat News • 2/5/2026
Summary
The opinion piece titled "Opinion: TrumpRx has a fundamental flaw" argues that the real winners from TrumpRx are pharmaceutical manufacturers.
Advertisement
Lindy Score Breakdown (V4.2)
57d
Age
1
Sources
from cluster
1384
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1384/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1384/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 57 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
Opinion: Medicare is restricting care for 1 million Americans based on a faulty assumption. Congress must intervene
Stat News • 2 days ago
Opinion: STAT+: Cardiology’s finally prioritizing prevention — but what will it look like?
Stat News • 1 day ago
Opinion: Medical misinformation wins when patients can’t see their doctors
Stat News • 1 day ago
Opinion: Subscription pricing could expand access to HIV prevention breakthrough while controlling costs
Stat News • Today
Opinion: My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine
Stat News • Today
Opinion: Medical marijuana should not be recommended for PTSD, anxiety, or depression
Stat News • 2 days ago
STAT+: How health care could gum up Trump’s reconciliation push
Stat News • 1 day ago
STAT+: NIH director’s invocation of Vannevar Bush’s legacy to promote Trump science policies sparks pushback
Stat News • 2 days ago
STAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
Stat News • 1 day ago
STAT+: The biotech scorecard for the second quarter: 23 stock-moving events to watch
Stat News • 2 days ago
Anti-Lindy Similar stories
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago